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OBJECTIVES The study compared the safety and efficacy of coronary artery stenting in aged and nonaged
patients and identified predictors of adverse clinical outcomes.
BACKGROUND Limited data are available on the outcomes of stenting in the aged ($80 years) compared to
nonaged patients.
METHODS The study was a pooled analysis of 6,186 patients who underwent coronary artery stenting in
six recent multicenter trials. A clinical events committee adjudicated clinical end points, and
quantitative angiography was performed by an independent core laboratory.
RESULTS There were 301 (4.9%) aged patients ($80 years). Compared to nonaged patients, aged
patients had a higher prevalence of multivessel disease (16.5% vs. 9.6%, p 5 0.001), unstable
angina (50.8% vs. 42.1%, p 5 0.003), moderate to severe target lesion calcification (30.4% vs.
15.3%, p 5 0.001) and smaller reference vessel diameter (2.90 mm vs. 2.98 mm, p 5 0.004).
Procedural success rate (97.4% vs. 98.5%, p 5 0.14) was similar in the two groups. In-hospital
mortality (1.33% vs. 0.10%, p 5 0.001), bleeding complications (4.98% vs. 1.00%, p , 0.001)
and one-year mortality (5.65% vs. 1.41%, p , 0.001) were significantly higher for the aged
patients. Clinical restenosis was similar for the two groups (11.19% vs. 11.93%, p 5 0.78).
Advanced age, diabetes, prior myocardial infarction and presence of three-vessel disease were
independent predictors of long-term mortality.
CONCLUSIONS Coronary artery stenting can be performed safely in patients $80 years of age, with excellent
acute results and a low rate of clinical restenosis, albeit with higher incidences of in-hospital
and long-term mortality, and vascular and bleeding complications compared to nonaged
patients. (J Am Coll Cardiol 2001;37:856–62) © 2001 by the American College of
Cardiology
The aged ($80 years) form the most rapidly growing
segment of the U.S. population (1). Because the prevalence
of coronary artery disease is higher in older patients, more of
them are presenting for percutaneous coronary interventions
(PCIs). These patients are more likely to have multivessel
coronary artery disease and heavy calcification of the vessels,
as well as other co-morbid conditions that place them at a
higher risk for peri-procedural complications (2–4). At the
same time, the use of coronary stents is steadily increasing to
include high-risk indications, including older patients, and
this currently constitutes over 60% of all coronary interven-
tional procedures.
Earlier studies have reported a low rate of procedure
success (,50% diameter stenosis without death, myocardial
infarction [MI], or emergent bypass surgery) and high rates
of major complications in older patients undergoing balloon
angioplasty, including up to 8.4% 30-day mortality and 14%
incidence of MI (2–14). In addition, older age has previ-
ously been reported to be a predictor of in-hospital mortal-
ity, as well as major ischemic and vascular complications in
various small single-center angioplasty and stent studies.
Data on the safety, efficacy and clinical outcomes of coro-
nary stenting in the aged using modern deployment tech-
niques and newer stent designs are limited.
The purpose of this study was to assess the success and
safety of coronary artery stenting in the aged compared to
the nonaged and to identify predictors of adverse outcomes
using prospectively collected data from a large cohort of
patients from recent multicenter clinical trials.
METHODS
Study design. Patients enrolled in six recent major clinical
trials of coronary stenting, between September 1995 and
March 1999, formed the cohort for this analysis. These
included four randomized trials comparing new stent de-
signs (MultiLink, NIR, AVE Micro II, Bard XT) with the
Palmaz-Schatz stent, Crossflex stent registry and the Stent
Antithrombotic Regimen Study (STARS) trial (aspirin only
and aspirin plus Coumadin groups were excluded), which
compared three antithrombotic regimens following success-
ful Palmaz-Schatz coronary stenting (15–21). All these
trials had similar inclusion and exclusion criteria. In general,
patients were to have focal (,20 mm) lesions with 50% to
99% diameter stenosis in a vessel, with visually estimated
reference diameter .3 mm, that could be covered by one to
two stents. Patients with recent preprocedural MI or left
ventricular ejection fraction ,30% were excluded from the
trials. All trials were coordinated by the Cardiovascular Data
Analysis Center (CDAC, Boston, Massachusetts). Primary
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data as well as quantitative angiographic data (using CMS-
GFT algorithm) for each of these trials were collected
prospectively and entered in separate databases at the
CDAC using Microsoft Access 2.0. Following data clean-
ing and electronic validation of data entry for each study
database, standard data tables were generated and then
combined into a pooled database with unique patient
identification.
Study population and stenting protocol. All patients
treated within the six clinical trials who received at least one
coronary stent and who were treated with aspirin and
ticlopidine following the stent procedure were eligible for
this analysis. The pooled data set included 6,186 patients
who underwent stenting of 6,219 target lesions. The stent-
ing protocol for each study included routine high-pressure
postdilation with recommended balloon: artery ratios of
1.1–1.2. Aspirin 325 mg daily and ticlopidine 250 mg twice
daily for four weeks formed the standard postprocedure
antithrombotic regimen. Use of Gp (glycoprotein) IIb/IIIa
inhibitors was discouraged in all of the studies, but they
could be used at the discretion of the investigator and
accounted for only 7.6% of patients overall. All patients
were followed at prespecified points for 9 to 12 months in
the individual trials, and a subgroup of patients had routine
angiographic follow-up at 6 to 9 months.
Definitions. Myocardial infarction (MI) included either
Q-wave MI (QMI) (defined as presence of new regional
pathologic Q-waves as reported by the blinded electrocar-
diogram [ECG] core laboratory) or non-QMI (defined as
CK-MB [creatine kinase, MB fraction] values greater than
three times normal or total CK more than two times the
upper limit of normal for each respective clinical site, in the
absence of new Q-waves). Vascular complications included
access site-related hematoma .4 cm, pseudoaneurysm,
atrioventricular (AV) fistula, retroperitoneal bleed or vascu-
lar surgical repair. Bleeding complications were reported as
any procedure-related blood loss requiring transfusion. Stent
thrombosis was defined as angiographic documentation of
stent occlusion, sudden unexplained death within 30 days of
the stenting procedure when the stent was not known to be
patent, recurrent MI in the target vessel territory, or urgent
target lesion revascularization (TLR). Either TLR or TVR
(target vessel revascularization) required the presence of
clinical or functional evidence of ischemia and .50%
stenosis by quantitative coronary angiography (QCA) or the
presence of a restenotic lesion .70% by QCA in the
absence of documented ischemia. An independent Clinical
Events Committee (CEC), blinded to the treatment assign-
ment for randomized cohorts, adjudicated all clinical events.
Justification for pooled analyses. These prospective stud-
ies, which were performed at the same clinical sites over a
narrow time period, had nearly identical inclusion criteria,
stenting protocols, similar case report forms with entry in
standard databases, clinical follow-up and end point defini-
tions as well as event adjudication by the same CEC for
each study. Furthermore, the same angiographic core labo-
ratory (Washington Hospital Center, Washington, D.C.)
performed the qualitative and quantitative analyses for each
study. The similarity of baseline patient and lesion charac-
teristics across the various studies further validates the
uniformity of the studies (15–21).
Statistical analysis. The primary analysis consisted of
comparison of parameters in the two cohorts stratified by
age. Continuous variables (e.g., minimal luminal diameter)
were compared using the Student t test, and categorical data
were compared using the chi-square test (or the Fisher’s
exact test where appropriate). A two-sided p value of p ,
0.05 was required for statistical significance. Survival esti-
mates were computed using Kaplan-Meier methods and
compared using log-rank tests. Stepwise multivariable anal-
ysis using logistic regression models was performed to
identify independent predictors of each end point. Several
different multivariable models for predictors of death and
vascular complications were constructed. Models that had a
better discriminatory ability (higher c-statistic) and calibra-
tion (higher p value for the Hosmer-Lemeshow x2 statistic)
were used. Missing data were not imputed, and mortality
rates were not different between patients with complete
versus missing data for the covariates evaluated. All statis-
tical analyses were performed using SAS for Windows
(version 6.12, SAS Institute, Cary, North Carolina).
RESULTS
Baseline clinical and angiographic characteristics. Of the
6,186 patients undergoing stenting, there were 301 aged
patients, which constituted 4.9% of the study population.
Significant differences existed in the prevalence of many
established risk factors for coronary artery disease (Table 1).
Aged patients were more likely to present with unstable
angina and to have multivessel disease.
Angiographically, the aged patients had slightly but
significantly smaller reference vessel and lesion length, and
they were more likely to have moderate to severely calcified
target lesions (Table 2). Other angiographic characteristics
including vessel treated and American College of Cardiol-
ogy/American Heart Association (ACC/AHA) lesion class
were not significantly different between the two age groups.
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft
EPISTENT 5 Evaluation of Platelet IIb/IIIa Inhibitor
for Stenting Trial
Gp 5 glycoprotein
MI 5 myocardial infarction
PCI 5 percutaneous coronary intervention
QCA 5 quantitative coronary angiography
QMI 5 Q-wave myocardial infarction
STARS 5 Stent Antithrombotic Regimen Study
TLR 5 target lesion revascularization
TVR 5 target vessel revascularization
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Procedural and angiographic results. In keeping with a
higher prevalence of heavily calcified lesions, aged patients
were more likely to have pretreatment with rotational
atherectomy. Otherwise, procedural characteristics (Table
3) were similar with nearly identical balloon:artery ratios
and maximum post-stent balloon inflation pressures. Sig-
nificant dissections before stenting were less common in
aged patients, and aged patients required significantly
shorter total stent length per treated vessel. Overall, lesion
success and procedure rates were similar between the two
age groups.
In-hospital major clinical events. In-hospital mortality
was significantly higher in the aged (Table 4). Peri-
procedural non-QMI was nonsignificantly higher in the
aged group. Aged patients also had a significantly higher
incidence of vascular and bleeding complications.
Clinical follow-up. The mean follow-up time was 282 6
85 days (Table 5). The one-year mortality in the aged group
was significantly higher than in the nonaged (Fig. 1;
Kaplan-Meier estimate 7.5% vs. 1.6%, log-rank p 5
0.0001). There was no significant difference in the incidence
of recurrent MI, TLR or TVR.
Multivariable modeling for predictors of mortality.
Older age was a significant independent predictor of one-
year mortality, with a 5% increase in risk per decade of life
(per decade, odds ratio [OR] 1.05; 95% confidence interval
[CI] 1.03–1.07, Table 6). The other significant predictors of
mortality included history of prior MI (OR 2.03; 95% CI
1.35–3.07), presence of diabetes (OR 1.97; 95% CI 1.29–
3.02) and three-vessel disease (OR 1.62; 95% CI 1.25–
2.10).
Multivariable modeling for predictors of vascular and
bleeding complications. In-hospital repeat revasculariza-
tion (OR 9.94; 95% CI 3.93–25.15), female gender (OR
3.49; 95% CI 2.31–5.27) and older age (OR 1.06 per dec-
ade; 95% CI 1.04–1.08) were independent predictors of the
occurrence of vascular or bleeding complications (Table 7).
DISCUSSION
Elderly patients have traditionally been considered a
high-risk population for PCIs with a higher incidence
of procedural failure and complications compared to
younger patients (2–14). Our study of 301 patients $80
years old represents the largest reported series of aged
Table 1. Baseline Clinical Characteristics
Clinical
Characteristics
Aged
(n 5 301
patients)
Nonaged
(n 5 5,885
patients)
p
Value
Age (mean 6 SD) 83.1 6 2.9 61.3 6 10.4
Female (%) 58.1 32.7 , 0.001
Diabetes mellitus (%) 17.3 21.2 0.13
Hypertension (%) 69.1 57.5 , 0.001
Current smoking (%) 4.4 32.8 , 0.001
Dyslipidemia (%) 24.2 42.5 , 0.001
Previous PTCA (%) 9.3 11.3 0.35
Previous CABG (%) 11.6 8.5 0.07
Previous MI (%) 34.8 33.7 0.70
Unstable angina (%) 50.8 42.1 0.003
Three-vessel disease (%) 16.5 9.6 0.001
Left ventricular
ejection fraction
(%, mean 6 SD)
55.0 6 12.1 55.8 6 11.2 0.29
CABG 5 coronary artery bypass graft; MI 5 myocardial infarction; PTCA 5
percutaneous transluminal coronary angioplasty; SD 5 standard deviation.
Table 2. Baseline Angiographic Findings (per Angiographic Core Laboratory)
Lesion
Characteristics
Aged
(n 5 304 lesions)
Nonaged
(n 5 5,909 lesions)
p
Value
Vessel location
Left anterior descending artery (%) 42.8 40.9
0.18
Left circumflex artery (%) 20.7 21.3
Right coronary artery (%) 35.2 37.1
Left main coronary artery (%) 0.7 0.3
SVG/LIMA (%)* 0.7 0.4
Characteristics (%)
Ulceration 10.5 9.9 0.76
Tortuosity 5.2 5.4 1.00
Eccentric (%) 37.2 38.2 0.76
Moderate-severe calcification 30.4 15.3 0.001
Thrombus 2.4 3.1 0.60
Lesion morphology† (%)
A 8.1 8.7
0.44
B1 24.8 28.9
B2 52.3 47.5
C 14.7 14.9
Reference vessel diameter (mm) 2.90 6 0.53 2.98 6 0.52 0.004
Lesion minimal lumen diameter (mm) 1.01 6 0.42 1.04 6 0.43 0.23
Diameter stenosis (%) 64.9 6 12.9 64.9 6 13.6 0.96
Lesion length (mm) 12.0 6 6.9 12.9 6 7.0 0.03
*SVG 5 saphenous vein graft; LIMA 5 left internal mammary artery; †American College of Cardiology/American Heart
Association lesion class.
}
}
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patients undergoing coronary artery stenting, and more
notably in the era of new second-generation stents and
routine high-pressure dilation. Aged patients in our study
had .97% procedure success rate despite smaller reference
vessel diameters and more prevalent calcification, albeit with
a significantly higher incidence of both in-hospital and
one-year mortality compared to the nonaged patients.
Procedural results and acute clinical outcomes. Al-
though the lesion complexity by ACC/AHA classification
was not significantly different in the aged patients, the
reference vessel diameter was significantly smaller, and
heavily calcified lesions were more frequent, accounting for
the associated greater use of pre-stenting rotational atherec-
tomy. Similar findings have been reported in prior studies
(4,5). Despite these unfavorable characteristics, the lesion
success rate was high. The frequency of procedure success
(defined as lesion success in the absence of death, MI or
emergent coronary artery bypass graft [CABG]) was also no
different from nonaged patients and was somewhat higher
than that reported by DeGregorio et al. (4) in their recent
single-center study of 137 patients $75 years (90% vs. 93%,
p 5 NS). This difference may reflect a healthier population
enrolled in the representative clinical trials. Of note, dissec-
tions prior to stenting were slightly less frequent in aged
patients, and this accounts in part for the significantly
shorter stent lengths that were required.
Mortality and aged patients. The aged patients had a
higher incidence of in-hospital mortality (1.33% vs. 0.10%,
p 5 0.001) compared to the nonaged patients, although this
incidence was still lower than the 2.2% to 3.1% in-hospital
mortality previously reported (2,4). Not surprisingly, age
was an independent predictor of overall mortality at one
year, with an increased risk of 5% per decade of life. This
increase was driven primarily by the continued increased risk
for death more than 30 days after the index procedure (Fig.
1). Aged patients had a higher frequency of multivessel
coronary artery disease, and the worse prognosis is likely a
reflection of the expected poorer outcomes of patients with
more severe and diffuse disease. There are limited compar-
ative data on the long-term mortality in aged patients
undergoing stenting, but the available studies have shown
similar results. Abizaid et al. (2) reported 4.8% one-year
mortality after stenting in subjects .80 years old. Among
137 stented patients .75 years old, DeGregorio et al. (4)
reported a procedural mortality rate of 2.2% and an overall
7.3% mortality rate through one year of follow-up.
Myocardial infarction and aged patients. An increased
risk for peri-procedural MI has been associated with in-
Table 3. Procedural and Angiographic Data (per Angiographic Core Laboratory)
Lesion
Characteristics
Aged
(n 5 304 lesions)
Nonaged
(n 5 5,909 lesions)
p
Values
Pretreatment rotational atherectomy (%) 13.3 5.4 , 0.0001
Lesion success (%) 99.3 99.5 0.68
Procedure success (%) 97.4 98.5 0.14
Present dissection .grade B (%) 13.7 17.9 0.08
Final dissection .grade B (%) 7.4 6.4 0.50
Final TIMI-3 flow (%) 99.0 99.5 0.30
Postprocedure in-lesion MLD (mm) 2.47 6 0.50 2.52 6 0.49 0.08
Postprocedure in-stent MLD (mm) 2.77 6 0.43 2.79 6 0.43 0.51
Postprocedure in-stent diameter stenosis (%) 4.7 6 11.9 7.4 6 11.5 , 0.001
Balloon: artery ratio 1.27 6 0.2 1.25 6 0.2 0.11
Stent length per vessel (mm) 20.3 6 10.3 21.9 6 12.3 0.02
Maximum post dilation pressure (atm) 14.4 6 4.2 14.8 6 4.4 0.16
*NHLBI dissection grade.
Lesion success was defined as attainment of ,50% diameter stenosis by QCA. Procedure success required lesion success in the
absence of in-hospital death, QMI or emergent CABG.
Table 4. In-Hospital Major Clinical Events
End
Points
Aged
(n 5 301 pts)
Nonaged
(n 5 5,885 pts)
p
Values
Death (%) 4 (1.33) 6 (0.10) 0.001
Myocardial infarction (%) 29 (9.63) 445 (7.56) 0.18
QMI 1 (0.33) 40 (0.68) 0.72
Non-QMI (CK-MB . 33 normal) 28 (9.30) 405 (6.88) 0.13
Target lesion revascularization (%) 1 (0.33) 48 (0.82) 0.73
PTCA 0 (0) 28 (0.48) 0.64
CABG 1 (0.33) 23 (0.39) 1.00
Stent thrombosis (%) 1 (0.33) 28 (0.48) 1.00
Vascular complications (%) 15 (4.98) 70 (1.19) , 0.001
Surgery for vascular complications (%) 1 (0.33) 20 (0.34) 1.00
Bleeding requiring transfusion (%) 15 (4.98) 59 (1.00) , 0.001
CABG 5 coronary artery bypass graft; PTCA 5 percutaneous transluminal coronary angioplasty; QMI 5 Q-wave myocardial
infarction.
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creased plaque burden and extent of coronary artery disease
(22,23). Certainly, in this aged population with higher
frequency of multivessel disease and smaller reference vessel
size it is likely that overall plaque burden was also increased.
Furthermore, greater use of rotational atherectomy in the
aged patients places them at a higher risk for peri-
procedural MI (24). Previous reports have suggested an
incidence of 0.4% to 2.2% for postprocedural MI in older
patients (2–4,6). In our study no significant difference was
seen in the incidence of MI in the aged patients compared
to the nonaged patients (9.63% vs. 7.56%, p 5 0.18),
although the overall higher incidence of peri-procedural MI
in both age groups may be due to the greater use of
rotational atherectomy as well as routine and complete
ascertainment of cardiac enzyme data following PCIs.
Vascular complications and aged patients. Along with
the change in stent designs and high-pressure dilation, there
has been a dramatic change in antithrombotic regimens
following stent implantation, as oral antiplatelet therapy
with aspirin and thienopyridines has replaced more aggres-
sive anticoagulation protocols. Although the overall inci-
dence of vascular complications has decreased with im-
provement in antithrombotic protocols and improved
sheath management, older patients and women continue to
have a higher incidence (4,6,13,15). Aged patients in our
study similarly had more frequent postprocedural vascular
and bleeding complications. Plausible explanations include
more aggressive anticoagulation of these patients with
complex lesion morphology, different pharmacodynamic
effects of heparin in the elderly, and increased risk for
vascular injury due to underlying peripheral vascular disease
(25).
Because the overall use of platelet GpIIb/IIIa inhibitors
was limited in our study (7.6%), we cannot assess the effects
of these agents in the aged cohort. Certainly, the
EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for
Stenting Trial) study has recently shown a reduction in
peri-procedural non-QMI and one-year mortality with use
of abciximab combined with coronary stenting compared to
stenting without abciximab and balloon angioplasty with
abciximab (26,27). Bleeding was not increased with use of
abciximab in that study, but given the increased serious
bleeding complications in aged patients in our study pre-
dominantly not receiving GpIIb/IIIa inhibitors, use of these
agents in aged patients will require careful consideration of
the benefits and risks.
Restenosis and aged patients. The aged patients in our
study had a favorable long-term clinical restenosis outcome
with no difference in TLR compared with nonaged patients
during one-year follow-up (8.30% vs. 10.90%); the rates of
Figure 1. Kaplan-Meier curve of one-year survival in the aged and nonaged
patients.
Table 5. Long-Term Cumulative Clinical Events
End Points
Aged
(n 5 301)
Nonaged
(n 5 5,885)
p
Value
Average follow-up time (days) 262 6 95 283 6 84 0.81
Death (%) 17 (5.65) 83 (1.41) , 0.001
Myocardial infarction (MI) (%) 32 (10.63) 503 (8.55) 0.21
QMI 1 (0.33) 27 (0.46) 1.00
Non-QMI 31 (10.30) 443 (7.53) 0.09
Target lesion revascularization (%) 25 (8.30) 656 (10.90) 0.19
Target vessel revascularization (%) 31 (11.19) 646 (11.93) 0.78
Vascular complications (%) 16 (5.32) 96 (1.63) , 0.001
Surgery for vascular complications (%) 2 (0.66) 44 (0.75) 1.00
Bleeding requiring transfusion (%) 15 (4.98) 67 (1.14) , 0.001
Stroke (%) 2 (0.66) 30 (0.51) 0.67
QMI 5 Q-wave myocardial infarction.
Table 6. Multivariable Modeling and Predictors of Mortality at
One Year
Variable
Univariate
Odds Ratio
(95% CI)
Multivariable
Odds Ratio
(95% CI)
Age (per decade) 1.06 (1.04,1.08) 1.05 (1.03,1.07)
Prior MI 1.99 (1.33,2.97) 2.03 (1.35,3.07)
Diabetes mellitus 2.31 (1.54,3.47) 1.97 (1.29,3.02)
Three-vessel disease 1.95 (1.52,2.50) 1.62 (1.25,2.10)
Female gender 1.64 (1.11,2.44) 1.48 (0.97,2.26)
Prior CABG 3.03 (1.87,4.90) —
Unstable angina 1.57 (1.01,2.45) —
LVEF (per %) 0.94 (0.92,0.96) —
In-hospital MI 2.30 (1.34,3.96) —
c 5 0.732, Hosmer-Lemeshow x2 p 5 0.181. (The c-statistic is a measure of the
discriminatory ability of the model. The Hosmer-Lemeshow x2 goodness-of-fit
statistic evaluates the calibration of the model; a model with perfect agreement
between the predicted and observed outcomes would yield a p value of 1).
CABG 5 coronary artery bypass graft; CI 5 confidence interval; LVEF 5 left
ventricular ejection fraction.
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TVR were nearly identical. This is in contrast with higher
TLR rates in the consecutive series of older patients
reported by DiGregorio et al. (4) (28% vs. 19%, p 5 0.02),
but similar to the 11% versus 14% to 15% TLR rates
reported by Abizaid et al. (2). This probably reflects the
aggressive initial results obtained rather than a physiologic
difference in the restenosis process in the different age
populations. The reduced risk for restenosis associated with
the shorter lesion and stent lengths in the aged patients
might have also balanced other potential increased risks for
restenosis (28,29).
Study limitations. There are several limitations of this
study. First, the data are pooled from several randomized
trials. Because randomization by age is not possible and
the number of aged patients undergoing revascularization
procedures is still small, pooled analysis from similar
trials was the only practical way to assess events in this
group. Second, the outcome results may not be general-
izable to the wider “real-world” population of aged
patients undergoing stenting procedures; it is likely that
“healthier” aged patients were enrolled in the clinical
trials pooled for this analysis.
Conclusions. This analysis of 301 aged patients from a
pooled data set of over 6,000 patients treated with stents
demonstrates that stenting can be performed safely in this
high-risk group with excellent acute results and low rates of
clinical restenosis, albeit with a higher incidence of in-
hospital and long-term mortality and with vascular and
bleeding complications. Further studies will confirm
whether more aggressive risk factor modification combined
with selected use of coronary stenting will improve the
long-term cardiac mortality in the aged population. Al-
though the incidence of bleeding complications was lower
than previously reported, efforts such as less anticoagu-
lation, selective use of antiplatelet regimens (especially
GpIIb/IIIa agents) and use of smaller-sized sheaths
should be evaluated as measures to further reduce these
risks in older patients.
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